Asthma Diagnosis and Treatment Guideline
... Spirometry provides an objective measurement of asthma severity and response to therapy, and can be useful in assessing patients who may under-report or over-report their symptoms. Spirometry should be considered when: • Considering an initial diagnosis of asthma (or as part of differential diagnosi ...
... Spirometry provides an objective measurement of asthma severity and response to therapy, and can be useful in assessing patients who may under-report or over-report their symptoms. Spirometry should be considered when: • Considering an initial diagnosis of asthma (or as part of differential diagnosi ...
Probiotics in Pediatrics Jon A. Vanderhoof, M.D.
... their DNA, and/or soluble products are likely to provide the beneficial properties of live bacteria, but may be safer alternatives because the dose of these agents can be readily controlled and they are less likely to establish lifelong niches that may be difficult to undo. ...
... their DNA, and/or soluble products are likely to provide the beneficial properties of live bacteria, but may be safer alternatives because the dose of these agents can be readily controlled and they are less likely to establish lifelong niches that may be difficult to undo. ...
(ESC) guidelines for the management of atrial fibrillation
... Disclaimer. The ESC Guidelines represent the views of the ESC and were arrived at after careful consideration of the available evidence at the time they were written. Health professionals are encouraged to take them fully into account when exercising their clinical judgement. The guidelines do not, ...
... Disclaimer. The ESC Guidelines represent the views of the ESC and were arrived at after careful consideration of the available evidence at the time they were written. Health professionals are encouraged to take them fully into account when exercising their clinical judgement. The guidelines do not, ...
Deep vein thrombosis clinical case scenarios
... be applied to the care of adults presenting to the acute care setting. These cases assume that you are the lead clinician throughout the patient’s acute phase. Although it is acknowledged that in reality this is not likely, they have been developed in this way to facilitate learning and understandin ...
... be applied to the care of adults presenting to the acute care setting. These cases assume that you are the lead clinician throughout the patient’s acute phase. Although it is acknowledged that in reality this is not likely, they have been developed in this way to facilitate learning and understandin ...
Guidelines for the management of atrial fibrillation
... Disclaimer. The ESC Guidelines represent the views of the ESC and were arrived at after careful consideration of the available evidence at the time they were written. Health professionals are encouraged to take them fully into account when exercising their clinical judgement. The guidelines do not, ...
... Disclaimer. The ESC Guidelines represent the views of the ESC and were arrived at after careful consideration of the available evidence at the time they were written. Health professionals are encouraged to take them fully into account when exercising their clinical judgement. The guidelines do not, ...
university textbook of oral mucosal diseases (selected chapters)
... The diseases of the oral mucosa represent a very varied group of diseases of different etiology and seriousness. The conditions of the orofacial region cannot be taken out from the context of other medical fields as they are closely connected with internal and dermatovenerological diseases. On the b ...
... The diseases of the oral mucosa represent a very varied group of diseases of different etiology and seriousness. The conditions of the orofacial region cannot be taken out from the context of other medical fields as they are closely connected with internal and dermatovenerological diseases. On the b ...
Management of atopic eczema in children
... evidence-based treatment approaches to emerge for those with chronic or relapsing eczema. All patients should be started on once daily treatments as twice daily applications have shown no additional benefits.6 Pulsed treatment has also not shown any benefit over continuous treatment, and there is ...
... evidence-based treatment approaches to emerge for those with chronic or relapsing eczema. All patients should be started on once daily treatments as twice daily applications have shown no additional benefits.6 Pulsed treatment has also not shown any benefit over continuous treatment, and there is ...
Guidelines of care for the management of psoriasis and psoriatic arthritis F
... cases to illustrate how to practically use these guidelines in specific clinical scenarios. We will describe the approach to treating patients with psoriasis across the entire spectrum of this fascinating disease from mild to moderate to severe, with and without psoriatic arthritis, based on the 5 p ...
... cases to illustrate how to practically use these guidelines in specific clinical scenarios. We will describe the approach to treating patients with psoriasis across the entire spectrum of this fascinating disease from mild to moderate to severe, with and without psoriatic arthritis, based on the 5 p ...
Inherited disorders of folate transport and metabolism. In
... 2. Five inherited disorders of folate transport and metabolism have been well substantiated: methylene-H4Folate reductase de®ciency (MIM 236250); functional methyltetrahydrofolate (methyl-H4Folate):homocysteine methyltransferase (methionine synthase) de®ciency caused by mutations in the gene for met ...
... 2. Five inherited disorders of folate transport and metabolism have been well substantiated: methylene-H4Folate reductase de®ciency (MIM 236250); functional methyltetrahydrofolate (methyl-H4Folate):homocysteine methyltransferase (methionine synthase) de®ciency caused by mutations in the gene for met ...
Guidelines for the management of atrial fibrillation
... Disclaimer. The ESC Guidelines represent the views of the ESC and were arrived at after careful consideration of the available evidence at the time they were written. Health professionals are encouraged to take them fully into account when exercising their clinical judgement. The guidelines do not, ...
... Disclaimer. The ESC Guidelines represent the views of the ESC and were arrived at after careful consideration of the available evidence at the time they were written. Health professionals are encouraged to take them fully into account when exercising their clinical judgement. The guidelines do not, ...
PRODUCT INFORMATION REVLIMID® (lenalidomide)
... 10 mg and 50 mg. A single dose of lenalidomide up to 50 mg is not associated with prolongation of the QT interval in healthy male subjects. This indicates that lenalidomide is not expected to result in clinically significant prolongation of the QT interval in patients at the approved therapeutic dos ...
... 10 mg and 50 mg. A single dose of lenalidomide up to 50 mg is not associated with prolongation of the QT interval in healthy male subjects. This indicates that lenalidomide is not expected to result in clinically significant prolongation of the QT interval in patients at the approved therapeutic dos ...
Guidelines for the management of atrial fibrillation
... Disclaimer. The ESC Guidelines represent the views of the ESC and were arrived at after careful consideration of the available evidence at the time they were written. Health professionals are encouraged to take them fully into account when exercising their clinical judgement. The guidelines do not, ...
... Disclaimer. The ESC Guidelines represent the views of the ESC and were arrived at after careful consideration of the available evidence at the time they were written. Health professionals are encouraged to take them fully into account when exercising their clinical judgement. The guidelines do not, ...
Application for Inclusion of MILTEFOSINE On WHO Model List of
... and compared to each Essential Medicine in Section 9.4. The summary of comparative therapeutic indices (efficacy, safety, and feasibility) vs. the four agents currently on the List of Essential Medicines for leishmaniasis (pentavalent antimony, amphotericin B deoxycholate, liposomal amphotericin B, ...
... and compared to each Essential Medicine in Section 9.4. The summary of comparative therapeutic indices (efficacy, safety, and feasibility) vs. the four agents currently on the List of Essential Medicines for leishmaniasis (pentavalent antimony, amphotericin B deoxycholate, liposomal amphotericin B, ...
Bronchiectasis : its medical and surgical treatment
... (a) clubbing of fingers and toes due to increase in soft tissue about ter::ninal phalanges (b) an increase in the size of bones of the forearr;-} and leg due to proliferation of the osseous tissue.seen in the more severe cases (c) bonyexoe- ...
... (a) clubbing of fingers and toes due to increase in soft tissue about ter::ninal phalanges (b) an increase in the size of bones of the forearr;-} and leg due to proliferation of the osseous tissue.seen in the more severe cases (c) bonyexoe- ...
Pathogenesis and treatment of hyperkeratotic tinea pedis in Japan
... antifungal factors [8]. Patients with true hyperkeratotic tinea pedis are more liable to fungal infections than patients with quasihyperkeratotic tinea pedis are more resistant to fungi, and vesicles are sometimes seen in these patients. In patients with partial-type hyperkeratotic tinea pedis, tran ...
... antifungal factors [8]. Patients with true hyperkeratotic tinea pedis are more liable to fungal infections than patients with quasihyperkeratotic tinea pedis are more resistant to fungi, and vesicles are sometimes seen in these patients. In patients with partial-type hyperkeratotic tinea pedis, tran ...
ukmiqa441crusted
... ivermectin 3mg tablets (Stromectol) recommends a dose of ivermectin 200 micrograms/kg of body weight, followed by a second dose within 8 to 15 days and/or concomitant topical therapy. The US Centers for Disease Control and Prevention currently recommend topical permethrin 5% every 2-3 days for 1-2 w ...
... ivermectin 3mg tablets (Stromectol) recommends a dose of ivermectin 200 micrograms/kg of body weight, followed by a second dose within 8 to 15 days and/or concomitant topical therapy. The US Centers for Disease Control and Prevention currently recommend topical permethrin 5% every 2-3 days for 1-2 w ...
Croup Diagnosis and Management of Guideline for the
... equivalent in terms of effect and safety The duration of effect of epinephrine does not exceed 2 hours. This patients should not be discharged from medical care for at least 2 hours after receiving a dose of epinephrine. ...
... equivalent in terms of effect and safety The duration of effect of epinephrine does not exceed 2 hours. This patients should not be discharged from medical care for at least 2 hours after receiving a dose of epinephrine. ...
Clozapine: Balancing Safety with Superior Antipsychotic Efficacy
... Despite the risk of agranulocytosis, metabolic side effects, and a variety of cardiovascular problems, including myocarditis, the specific advantages of clozapine with regard to efficacy can still make it a prudent choice for as many as 30–40% of patients with schizophrenia or schizoaffective disord ...
... Despite the risk of agranulocytosis, metabolic side effects, and a variety of cardiovascular problems, including myocarditis, the specific advantages of clozapine with regard to efficacy can still make it a prudent choice for as many as 30–40% of patients with schizophrenia or schizoaffective disord ...
Section 3: Antiallergics and Medicines Used in Anaphylaxis
... and diphenhydramine for use in allergic rhinitis, urticaria and anaphylaxis. The evidence from five RCTs does show similar effectiveness and side effect profile of the two medications for both allergic rhinitis and urticaria. However, the review has shown significant evidence comparing efficacy and ...
... and diphenhydramine for use in allergic rhinitis, urticaria and anaphylaxis. The evidence from five RCTs does show similar effectiveness and side effect profile of the two medications for both allergic rhinitis and urticaria. However, the review has shown significant evidence comparing efficacy and ...
Antithrombotic Therapy in Children
... doses of VKAs (INR range, 1.5 to 1.9) or LMWH (anti-FXa level range, 0.1 to 0.3) be given until the CVL is removed (Grade 2C). If recurrent thrombosis occurs while the patient is receiving prophylactic therapy, we suggest continuing therapeutic doses until the CVL is removed but at least for a minim ...
... doses of VKAs (INR range, 1.5 to 1.9) or LMWH (anti-FXa level range, 0.1 to 0.3) be given until the CVL is removed (Grade 2C). If recurrent thrombosis occurs while the patient is receiving prophylactic therapy, we suggest continuing therapeutic doses until the CVL is removed but at least for a minim ...
Current management
... extensive,1 and pattern of disease (relapse frequency, course of disease, response to previous medications, side-effect profile of medication, extra-intestinal manifestation), before treatment decisions are made in conjunction with the patient. 5.1.1. Disease activity The principal scoring systems u ...
... extensive,1 and pattern of disease (relapse frequency, course of disease, response to previous medications, side-effect profile of medication, extra-intestinal manifestation), before treatment decisions are made in conjunction with the patient. 5.1.1. Disease activity The principal scoring systems u ...
A case-based approach to the dizzy patient
... Vestibular neuritis - Treatment • Corticosteroids controversial – 2011 Cochrane review found insufficient evidence for routine use – Studies show earlier return of vestibular function testing but mixed evidence for earlier recovery of ...
... Vestibular neuritis - Treatment • Corticosteroids controversial – 2011 Cochrane review found insufficient evidence for routine use – Studies show earlier return of vestibular function testing but mixed evidence for earlier recovery of ...
Practice Guideline - Ordination Dr. Simhandl
... guideline refers to a set of patient care strategies developed to assist physicians in clinical decision making. We anticipate that several guidelines will be published each year as they are completed and approved by the APA. Although the APA has been publishing specific recommendations about the pr ...
... guideline refers to a set of patient care strategies developed to assist physicians in clinical decision making. We anticipate that several guidelines will be published each year as they are completed and approved by the APA. Although the APA has been publishing specific recommendations about the pr ...
Granulomatous Meningoencephalomyelitis in Dogs
... Both normal and increased values have been obtained and probably depend on the severity of the disease and the skill of the clinician performing the measurement.16,24 Rarely, CSF protein electrophoresis is performed to further identify increased proteins.4 At this time, such information does not app ...
... Both normal and increased values have been obtained and probably depend on the severity of the disease and the skill of the clinician performing the measurement.16,24 Rarely, CSF protein electrophoresis is performed to further identify increased proteins.4 At this time, such information does not app ...
Ciclosporin - Dr Guan Lim MD FRCP
... How long do I have the infusion? The ciclosporin infusion is administered for 5 – 10 days. If your condition improved after 5 – 10 days, then you will be prescribed oral ciclosporin twice daily. (Please note: Grapefruit juice interact with ciclosporin, so it should only be consumed less than one hou ...
... How long do I have the infusion? The ciclosporin infusion is administered for 5 – 10 days. If your condition improved after 5 – 10 days, then you will be prescribed oral ciclosporin twice daily. (Please note: Grapefruit juice interact with ciclosporin, so it should only be consumed less than one hou ...
Management of multiple sclerosis
Several therapies for multiple sclerosis (MS) exist, although there is no known cure. Multiple sclerosis is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS).The most common initial course of the disease is the relapsing-remitting subtype, which is characterized by unpredictable attacks (relapses) followed by periods of relative remission with no new signs of disease activity. After some years, many of the people who have this subtype begin to experience neurologic decline without acute relapses. When this happens it is called secondary progressive multiple sclerosis. Other, less common, courses of the disease are the primary progressive (decline from the beginning without attacks) and the progressive-relapsing (steady neurologic decline and superimposed attacks). Different therapies are used for patients experiencing acute attacks, for patients who have the relapsing-remitting subtype, for patients who have the progressive subtypes, for patients without a diagnosis of MS who have a demyelinating event, and for managing the various consequences of MS.The primary aims of therapy are returning function after an attack, preventing new attacks, and preventing disability. As with any medical treatment, medications used in the management of MS may have several adverse effects, and many possible therapies are still under investigation. At the same time different alternative treatments are pursued by many patients, despite the paucity of supporting, comparable, replicated scientific study.This article focuses on therapies for standard MS; borderline forms of MS have particular treatments that are excluded.